About

Hubro Therapeutics develops immunotherapies for treatment of cancer. Our product candidates are novel neoantigen targeted cancer vaccines for activation of anti-cancer specific T cell immune responses. By providing increased levels of anti-cancer reactive T cells, and by combining with other immune-oncology treatments, it is our desire and strong hope to improve the lives of cancer patients. 

Hubro Therapeutics AS is a privately held Norwegian biotech company founded in 2018 and located in Oslo. Our focus is on development of novel proprietary cancer vaccines. We believe that cancer vaccines will play important roles for the further improvement of immunotherapy of cancer. By providing increased levels of anti-cancer reactive T cells it is our desire and sincere hope to improve the lives of cancer patients.


The vaccines are for activation of anti-cancer T cell immune responses and target neo-antigens caused by genetic frameshift mutation associated with MSI and cancer. MSI is also associated with high risk of development of hereditary cancers.

Hubro Therapeutics has an experienced international management and operational team and has an extensive network of industrial and academic partners for leveraging the development of our products. Our office is currently at The Oslo Cancer Cluster Incubator.